Medtronic PLC $MDT Holdings Cut by Orange Investment Advisors Inc.

Orange Investment Advisors Inc. trimmed its position in Medtronic PLC (NYSE:MDT) by 5.9% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 95,692 shares of the medical technology company’s stock after selling 6,000 shares during the period. Medtronic accounts for about 1.0% of Orange Investment Advisors Inc.’s portfolio, making the stock its 27th largest position. Orange Investment Advisors Inc.’s holdings in Medtronic were worth $8,257,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of MDT. Randolph Co Inc purchased a new stake in shares of Medtronic during the 3rd quarter valued at approximately $26,836,000. Provident Investment Management Inc. boosted its position in shares of Medtronic by 16.2% during the third quarter. Provident Investment Management Inc. now owns 17,175 shares of the medical technology company’s stock worth $1,482,000 after buying an additional 2,395 shares during the period. Code Waechter LLC boosted its holdings in Medtronic by 56.1% during the 3rd quarter. Code Waechter LLC now owns 5,772 shares of the medical technology company’s stock valued at $498,000 after acquiring an additional 2,075 shares during the period. Atlas Private Wealth Advisors purchased a new stake in Medtronic during the 3rd quarter worth approximately $305,000. Finally, Signaturefd LLC grew its stake in Medtronic by 10.3% during the 3rd quarter. Signaturefd LLC now owns 14,630 shares of the medical technology company’s stock worth $1,262,000 after purchasing an additional 1,362 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Stock Performance

Shares of MDT opened at $95.48 on Monday. The company’s 50 day simple moving average is $91.43 and its 200-day simple moving average is $85.29. The firm has a market cap of $122.13 billion, a PE ratio of 23.52, a price-to-earnings-growth ratio of 2.23 and a beta of 0.55. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.39 by $0.06. The firm had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. Medtronic’s revenue for the quarter was up 13.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, equities analysts predict that Medtronic PLC will post 5.98 EPS for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 16th. Investors of record on Friday, September 25th were given a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 3.0%. The ex-dividend date was Friday, September 25th. Medtronic’s payout ratio is 70.94%.

Analysts Set New Price Targets

A number of analysts recently weighed in on MDT shares. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research note on Saturday, October 3rd. TD Cowen reissued a “buy” rating and issued a $110.00 price objective on shares of Medtronic in a research report on Wednesday, September 30th. UBS Group reaffirmed a “cautious” rating on shares of Medtronic in a research report on Wednesday, October 14th. BTIG Research cut their price objective on shares of Medtronic from $100.00 to $99.00 and set a “buy” rating on the stock in a report on Monday, October 12th. Finally, Robert W. Baird increased their target price on shares of Medtronic from $91.00 to $100.00 and gave the company a “neutral” rating in a research report on Wednesday, September 2nd. Eighteen research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and an average target price of $102.88.

Insider Buying and Selling at Medtronic

In other Medtronic news, EVP Harry Kiil sold 1,483 shares of Medtronic stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the transaction, the executive vice president directly owned 42,186 shares in the company, valued at approximately $3,950,718.90. This trade represents a 3.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Geoffrey Martha sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $95.00, for a total value of $4,750,000.00. Following the completion of the transaction, the chief executive officer directly owned 277,866 shares in the company, valued at approximately $26,397,270. The trade was a 15.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 61,903 shares of company stock worth $5,889,203. 0.27% of the stock is currently owned by insiders.

Medtronic Profile

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.